New drug linked to fewer deaths among kidney patients undergoing hemodialysis
A new non-calcium phosphate binder, lanthanum carbonate (Fosrenol), has shown a reduction in mortality and cardiac death among kidney patients on hemodialysis compared to conventional phosphate binders. The study involved 647 patients who received Fosrenol therapy for two years.